Similarly, fatty acid synthase (FASN), the key enzyme of de novo lipogenesis, is found to be highly active in a large variety of cancers, and its up-regulation is associated with chemotherapeutic drug resistance [11, 12]. The gene discussed is FASN; the disease is cancer.